What it's for (Indications)
- Valdecoxib, formerly marketed under brand names such as NoviCoxib, was a selective cyclooxygenase-2 (COX-2) inhibitor NSAID that was historically indicated for the management of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and for the treatment of primary dysmenorrhea.
- It was developed to provide anti-inflammatory and analgesic effects while theoretically reducing the gastrointestinal side effects associated with non-selective NSAIDs.
- However, due to significant safety concerns, particularly regarding cardiovascular thrombotic events and severe cutaneous adverse reactions, valdecoxib was voluntarily withdrawn from the market globally in 2005 by its manufacturer and is no longer available for prescription or use.
- Therefore, while these were its approved indications, the drug is not currently used for any medical condition.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Historically, for the management of osteoarthritis and rheumatoid arthritis, the recommended dosage of valdecoxib was typically 10 mg orally once daily. For primary dysmenorrhea, the usual initial dose was 20 mg orally once daily, which could be increased to 40 mg once daily if necessary. It was intended for short-term use in acute pain conditions and for chronic use in inflammatory arthritides. However, as previously stated, valdecoxib has been withdrawn from the market worldwide since 2005 due to severe safety concerns, rendering these dosage recommendations purely historical and no longer applicable in current clinical practice. Patients should be aware that this medication is not available and alternative treatments should be discussed with a healthcare professional. |
Safety & Warnings
Common Side Effects
- While valdecoxib was marketed, common side effects observed were generally consistent with other NSAIDs, including headache, abdominal pain, dyspepsia, nausea, diarrhea, and peripheral edema.
- However, the drug was associated with several serious adverse events that ultimately led to its market withdrawal.
- These included a significantly increased risk of serious cardiovascular thrombotic events such as myocardial infarction (MI) and stroke, which could be fatal.
- Furthermore, like all NSAIDs, it carried risks of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which could also be fatal.
- Most critically, valdecoxib was particularly implicated in a heightened risk of severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and exfoliative dermatitis, some of which were fatal.
- These severe dermatological reactions were a primary driver for its global withdrawal.
Serious Warnings
- Black Box Warning: Valdecoxib was subject to stringent Black Box Warnings and was ultimately withdrawn from the market globally in 2005 due to severe safety concerns. These critical warnings encompassed: **1. Cardiovascular Thrombotic Events:** NSAIDs, including COX-2 selective NSAIDs like valdecoxib, were found to increase the risk of serious, and potentially fatal, cardiovascular thrombotic events, including myocardial infarction (MI) and stroke. This risk could occur early in treatment and increase with duration of use, particularly in patients with pre-existing cardiovascular disease or risk factors for cardiovascular disease. **2. Gastrointestinal Risk:** NSAIDs, including valdecoxib, cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and those with a history of peptic ulcer disease and/or GI bleeding were at greater risk. **3. Serious Skin Reactions:** Valdecoxib was specifically associated with an increased risk of serious and potentially fatal skin reactions, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and exfoliative dermatitis. This heightened risk of severe cutaneous adverse reactions (SCARs) was a primary and distinct factor that led to its voluntary market withdrawal. Due to the significant and unacceptable risks associated with valdecoxib, especially the severe cardiovascular thrombotic events and life-threatening dermatological reactions, the drug was removed from the market and is no longer available for prescription or use.
- Valdecoxib carried significant warnings that ultimately led to its global market withdrawal.
- All NSAIDs, including valdecoxib, were associated with an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which could be fatal.
- This risk could occur early in treatment and increase with duration of use.
- Valdecoxib was also associated with an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which could be fatal, occurring at any time without warning.
- A critical concern specific to valdecoxib was its association with a significantly higher incidence of serious skin reactions, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and exfoliative dermatitis, some of which were fatal.
- Furthermore, caution was advised in patients with pre-existing cardiovascular disease, hypertension, fluid retention, or severe hepatic or renal impairment.
- It was also contraindicated in patients with a history of allergic reactions to sulfonamides, aspirin, or other NSAIDs.
- Due to these profound safety concerns, valdecoxib is no longer available.
How it Works (Mechanism of Action)
Valdecoxib is a non-steroidal anti-inflammatory drug (NSAID) classified as a selective cyclooxygenase-2 (COX-2) inhibitor. Its primary mechanism of action involves the inhibition of the COX-2 enzyme, which is primarily induced by inflammatory stimuli and is responsible for the synthesis of prostaglandins involved in mediating pain, inflammation, and fever. By selectively inhibiting COX-2, valdecoxib aimed to reduce these inflammatory processes while sparing the cyclooxygenase-1 (COX-1) enzyme. COX-1 is constitutively expressed and responsible for producing prostaglandins that play crucial roles in maintaining gastric mucosal integrity, renal blood flow, and platelet aggregation. The selective inhibition of COX-2 was intended to provide anti-inflammatory and analgesic effects with a reduced risk of gastrointestinal side effects compared to non-selective NSAIDs that inhibit both COX-1 and COX-2. However, despite its selective mechanism, the serious cardiovascular and dermatological risks observed led to its withdrawal.
Commercial Brands (Alternatives)
No other brands found for this formula.